Clone:
NKVFS1
Type of antibody:
Primary antibodies
Isotype:
mouse IgG1κ
Applications:
FC, MICS, IF, IHC
Alternative names:
CD158A

Extended validation for KIR2D Antibody, anti-human

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with NKVFS1
REA1042++
HP-3E4++
HP-DM1++
HP-MA4-
Cells were incubated with an excess of purified unconjugated KIR2D (NKVFS1) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for KIR2D. Human peripheral blood mononuclear cells (PBMCs) were stained with KIR2D antibodies and with a suitable counterstaining. As a control, KIR2D antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for KIR2D. Human peripheral blood mononuclear cells (PBMCs) were stained with KIR2D antibodies and with a suitable counterstaining. As a control, KIR2D antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for KIR2D. Human peripheral blood mononuclear cells (PBMCs) were stained with KIR2D antibodies and with a suitable counterstaining. As a control, KIR2D antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for KIR2D. Human peripheral blood mononuclear cells (PBMCs) were stained with KIR2D antibodies and with a suitable counterstaining. As a control, KIR2D antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for KIR2D. Human peripheral blood mononuclear cells (PBMCs) were stained with KIR2D antibodies and with a suitable counterstaining. As a control, KIR2D antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for KIR2D. Human peripheral blood mononuclear cells (PBMCs) were stained with KIR2D antibodies and with a suitable counterstaining. As a control, KIR2D antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for KIR2D. Human peripheral blood mononuclear cells (PBMCs) were stained with KIR2D antibodies and with a suitable counterstaining. As a control, KIR2D antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for KIR2D. Human peripheral blood mononuclear cells (PBMCs) were stained with KIR2D antibodies and with a suitable counterstaining. As a control, KIR2D antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using KIR2D (NKVFS1). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using KIR2D (NKVFS1). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using KIR2D (NKVFS1). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for KIR2D Antibody, anti-human

Overview

The Anti-KIR2D antibody recognizes the killer immunoglobulin-like receptor (KIR) 2D subtype on human and non-human primate cells. It recognizes all KIRs bearing two extracellular Ig-like domains, and also both activating and inhibitory KIR isoforms (KIR2DS and KIR2DL, respectively). KIRs are expressed on CD56
dim
CD16
+
natural killer (NK) cells and a subset of CD8
+
T cells. KIRs contribute to the regulation of NK cell-mediated cytotoxicity. They are monomeric receptors possessing high allelic polymorphism with either two or three Ig-like extracellular domains (KIR2D or KIR3D, respectively). According to the length of their cytoplasmic tail, KIRs can be subdivided in long-tailed inhibitory KIRs (KIR2DL or KIR3DL) and short-tailed activating KIRs (KIR2DS or KIR3DS).

Alternative names

CD158A

Detailed product information

Technical specifications

CloneNKVFS1
Clonalitymonoclonal
Isotypemouse IgG1κ
Isotype controlIsotype Control Antibody, mouse IgG1
Hostmouse
Type of antibodyPrimary antibodies
Specieshuman, non-human primate
Cross-reactivity
rhesus monkey (
Macaca mulatta
)
AntigenKIR2D
Alternative names of antigenCD158A
Molecular mass of antigen [kDa]31-39
Distribution of antigenNK cells, T cells
Entrez Gene ID3806, 100132285, 3808, 3809, 3810, 3802, 3803, 3804, 3805, 57292
RRIDAB_2819517, AB_2660017, AB_2660018, AB_2660020, AB_871568, AB_2660021, AB_2660022, AB_2660025, AB_871569, AB_871567, AB_2819552

Resources for KIR2D Antibody, anti-human

Documents and Protocols

App notes/customer reports

Cross-reactivity of KIR antibodies

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for KIR2D Antibody, anti-human

Publications

  1. Hsu, K. et al. (2002) The killer cell immunoglobin-like (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol. Rev. 190: 40-52
  2. Selvakumar, A. et al. (1997) Polymorphism and domain variability of human killer cell inhibitory receptors. Immunol. Rev. 155: 183-196

Related products for
KIR2D Antibody, anti-human

7 products available | view all

Seems like you are coming from USA!
Do you want to visit our website in your country?